APOB and atherosclerosis: It is now accepted that using ApoB to assess ASCVD risk in hypertriglyceridaemia (2–10 mmol/L) better reflects the total number of atherogenic particles than do LDL-C or non-HDL-C, particularly in patients with hypertriglyceridemia (25, 29–36).